Western blot analysis was used to determine the relative extent of PI3K pathway activation in 2 liposarcoma cases that carried an activating PIK3CA mutation compared with 3 liposarcoma samples for which PIK3CA mutations were not observed, as well as 3 lipoma samples (Figure 2). The gene discussed is PIK3CA; the disease is liposarcoma.